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Objective: The aim of the present study was to define the role of luteinizing hormone
receptor (LH-R) expression in endometrial cancer (EC), using preclinical mouse models, to
further transfer these data to the clinical setting.
Materials and Methods: The role of LH-R over-expression was studied using EC cells
(Hec1A, e.g., cells with low endogenous LH-R expression) transfected with the LH-R
(Hec1A-LH-R). In vitro cell proliferation was measured through the WST-1 assay, whereas
cell invasion was measured trough the matrigel assay.The effects of LH-R over-expression
in vivo were analyzed in an appropriately developed preclinical mouse model of EC, which
mimicked postmenopausal conditions. The model consisted in an orthotopic xenograft of
Hec1A cells into immunodeficient mice treated daily with recombinant LH, to assure high
levels of LH.
Results: In vitro data indicated that LH-R over-expression increased Hec1A invasiveness.
In vivo results showed that tumors arising from Hec1A-LH-R cells injection displayed
a higher local invasion and a higher number of distant metastases, mainly in the lung,
compared to tumors obtained from the injection of Hec1A cells. LH withdrawal strongly
inhibited local and distant metastatic spread of tumors, especially those arising from
Hec1A-LH-R cells.
Conclusion: The over-expression of the LH-R increases the ability of EC cells to undergo
local invasion and metastatic spread. This occurs in the presence of high LH serum
concentrations.
Keywords: endometrial carcinoma, LH-R, LH, invasion, metastasis, mouse model
INTRODUCTION
Endometrial carcinoma (EC) is nowadays the most common gyne-
cologic malignancy and the most frequent among infiltrating
tumor of the female genital tract (1). Although EC is generally
considered not aggressive, with a good prognosis and an overall
survival (OS) rate of about 80%, there is still a group of patients
with a high risk of recurrence and decreased OS (1–3). The latter
is mainly related to the extra-pelvic spread of the cancer, with the
onset of distant metastases, mainly to the lung (4, 5). Hence, fur-
ther advances in controlling local and distant metastatic disease of
EC are needed. As an example, it is worth noting that the methyla-
tion profile of EC can help to distinguish malignant from benign
lesions (6).
It is known that ECs arising in the menopause are more aggres-
sive and usually unlinked to estrogen secretion. It has been previ-
ously reported that estrogen independent ECs might be sensitive
to elevated levels of luteinizing hormone (LH) (7), an event that
characterizes the postmenopause. This hypothesis was first sup-
ported by the demonstration by Lin et al. that the gene encoding
the LH receptor (LH-R) was expressed in primary human ECs (7,
8) and that the addition of LH influences proliferation of EC cell
lines (9, 10). Afterward, our group better defined the role of LH in
tumor progression of EC, demonstrating that LH is able to induce
an in vitro invasive phenotype to EC cells (11). Such effect relies on
the activation of LH-R and hence of protein kinase A (PKA), which
in turn induces a functional activation of beta 1 integrin receptors
and the subsequent secretion of active matrix metalloproteinase-2
ending in the triggering of cell invasiveness (11).
We also provided evidence that LH-R mRNA is expressed in the
great majority of a cohort of primary ECs and that cells obtained
from primary ECs can be triggered to invade by LH addition
(12). A good correlation was found between the level of LH-R
mRNA expressed by primary EC and the degree of LH-induced
cell invasiveness in vitro (12, 13).
However, the role of LH-R in in vivo models is currently lacking.
The aim of the present study was to define the role of LH-
R expression in EC, using preclinical mouse models, to further
transfer these data to the clinical setting.
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MATERIALS AND METHODS
CELL CULTURE AND TRANSFECTION
The human cell line Hec1A were grown in DMEM High Glucose
(DMEM) (EuroClone) supplemented with 2% l-Glut, 10% fetal
bovine serum (FBS) (Hyclone) and 1% penicillin/streptomycin.
To establish transfected cell lines, the rLH-pcDNA III expres-
sion vector (a gift from Dr. Rodiem Patrice, Endocrinologie CHU
d’Angers) and the empty expression vector (pcDNA III) were
transfected into Hec1A cells with Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instruction (Hec1A and Hec1A-
LH-R). Forty-eight hours after transfection, cells were plated, and
selected with G418 (800µg/ml) for 2 weeks. The medium was
changed every 3 days. Clones were expanded for further analysis.
RNA ISOLATION, cDNA SYNTHESIS, AND REAL-TIME QUANTITATIVE
PCR
Total RNA, cDNA synthesis, and real-time quantitative PCR (RQ-
PCR) for the quantification of LH-R mRNA were performed as
reported in Ref. (12).
PROLIFERATION ASSAY
Cell proliferation was evaluated by a colorimetric assay WST-1
(Roche). For this procedure, cells were synchronized by overnight
serum starvation and seeded in 96-well plates at a density of
2.5× 104 cells/100µl, in DMEM+ 2%l-Glut+ 10% FBS. Cells
were incubated for 24 h in the presence/absence of human recom-
binant LH (rLH) (Ovitrelle®) at the concentration of 0.3 UI/ml.
Assays were performed by adding WST-1 directly to the culture
wells and incubating the plates for 20 min at 37°C. Plates were
then read by ELISA microplate (ELX800 Universal microplate
reader, Bio-TecK instruments) at 450 nm. All data were normalized
to the absorbance value of the culture medium (DMEM+ 2%l-
Glut+ 10%FBS). Experiments were performed in triplicate.
MATRIGEL INVASION ASSAY
Hec1A and Hec1A-LH-R were resuspended in DMEM+ 2%l-
Glut containing 250µg/ml heat-inactivated BSA (DMEM+BSA).
Cell suspensions (200µl) containing 50,000 cells, were seeded into
the upper well of a Boyden chamber (NeuroProbe), separated
from the lower compartment (filled with DMEM+BSA) by a
porous membrane (8µm pore diameter) previously coated with
50µl of matrigel at the final concentration of 250µg/ml (Becton
Dickinson). Cells were incubated for 24 h in presence/absence of
human rLH 0.3 UI/ml (Ovitrelle®). Boyden chambers were incu-
bated at 37°C in humidified atmosphere containing 5% CO2 in
air for 24 h. Cells remaining attached to the upper surface of the
filters were carefully removed with cotton swabs. Migrated cells,
which remained layered onto the lower face of the porous mem-
brane, were fixed with absolute methanol at 4°C overnight and
stained with Diff-Quick staining solution (Dade–Behring Hold-
ing GmbH). Cells were counted on the whole migration field, at
×40 magnification.
IN VIVO MODELS
All in vivo experiments were performed at the Laboratory
of Genetic Engineering for the Production of Animal Models
(LIGeMA) at the Animal Facility of the University of Firenze.
Xenograft model
About 5× 106 cells (Hec1A and Hec1A-LH-R cell lines), resus-
pended in 100µl culture medium were injected s.c. into the flanks
of nude mice (females, 4 weeks old). Mice were divided into two
groups for each cell line:
- group 1 (five mice/group) received saline;
- group 2 (five mice/group) received i.p. injections of rLH
(Ovitrelle®) (5 UI/mouse) daily for 4 weeks. After 4 weeks of
treatment mice were sacrificed.
Orthotopic model
Subcutaneously, xenografts were established by the injection of
5× 106 cells as reported above. For orthotopic implantation, 27
nude mice were anesthetized with i.p. 2% Avertin, and the lower
abdomen was swabbed with 70% alcohol. A longitudinal inci-
sion of the lower abdomen of about 15 mm in length was made
(medial laparotomy). The retro peritoneum was then opened and
the uterus visualized. The model consisted in the implantation of
one tissue block (1 mm3 and weighting about 40 mg each) onto
the posterior face of the uterus making a pocket and fixed with
a surgical suture. The choice to orthotopically implant a tissue
block instead of cell suspension is to maintain the full metastatic
potential of the original tumor (maintaining a 3D tissue archi-
tecture, cell cell contact and tumor angiogenesis) (14). The tissue
blocks were derived from masses developed in nude mice injected
s.c with Hec1A or Hec1A-LH-R cells. The organs were reintro-
duced into the abdominal cavity and the retro peritoneum and
skin were then closed with surgical suture. Mice for each cell line
were divided in two groups and treated with 5 UI/daily of r-LH
(Ovitrelle®) or saline solution in the case of control group. Seven
weeks later, the animals were sacrificed by cervical dislocation for
necropsy. Then, for all of the animals, the peritoneal cavity was
opened and examined macroscopically.
HISTOLOGY AND IMMUNOSTAINING
Samples of different organs were fixed in formalin and processed
for routine histological examination. Histological analysis was
carried out on 5µm paraffin sections stained with hematoxylin
and eosin (H&E). For immunohistochemistry (IHC), slides were
stained with the following antibody: anti-MHC class I antibod-
ies (H-300) (IHC: 1: 100) (Santa Cruz) [as previously described
in (15)].
QUANTITATIVE DETERMINATION OF LH CONCENTRATION IN NUDE
MICE
Mice (three mice per group) were treated with rLH (Ovitrelle®)
at the dose of 5 UI, daily, or with saline. LH serum levels were
measured 6 h after i.p. injection of the drug, collecting blood
samples (100µl) and quantifying LH concentrations with the
LH Enzyme Immunoassay Kit (Genway, Biotech Inc), following
manufacturer’s instruction. High and stable LH serum concen-
trations were detected in the rLH–treated vs. the control group:
10.94± 2.31 vs. 0.02± 0.01 ng/ml; p< 0.01 (Student’s t test).
STATISTICAL ANALYSIS
All averaged data are presented as mean± SEM. The statisti-
cal significance of differences between experimental group was
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calculated with the Mann–Whitney test, Kruskal–Wallis Test, or
Student’s t test, with a p< 0.05 being considered as statistically
significant.
RESULTS
We produced Hec1A cells, e.g., an EC cell line with low endogenous
expression of LH-R (11), transfected with the human LH-R cDNA
in the pcDNA III expression vector. The expression of the LH-R
transcript in the transfected cell lines, quantified by RQ-PCR, was
13-fold higher than in Hec1A cells. Both cell proliferation and
invasion were tested in either cell lines, in the absence or in the
presence of rLH (0.3 UI/ml). The proliferation rate of Hec1A-LH-
R cells was not significantly different from that of control Hec1A
cells, and it was not affected by LH treatment (Figure 1A). On the
contrary, the invasion capacity of Hec1A-LH-R cells was signifi-
cantly higher than control Hec1A cells, either in the absence or in
the presence of external LH (Figures 1B,B′).
These data confirmed previous indications (11, 12) that LH-R
over-expression affects EC cell invasiveness, more than prolifera-
tion.
We then developed a mouse preclinical model of EC which
also mimicked the hormonal conditions of the menopause (i.e.,
high levels of circulating LH) which is the period of higher inci-
dence of EC. The model consisted in the implantation of a tissue
block (1 mm3), derived from subcutaneous masses developed in
nude mice injected with EC cells. Either Hec1A cells or Hec1A-
LH-R cells were nude to develop subcutaneous masses into the
posterior face of the uterus of nude female mice. Nude female
mice show severe deficiencies in the reproductive functions such
as delayed ovulation and ensuing sterility, and have undetectable
concentrations of LH in the serum as previously reported (16) and
confirmed in our model by LH Enzyme Immunoassay Kit deter-
mination (see Materials and Methods for details). Hence, to obtain
high and stable LH concentrations, mice were treated with rLH,
daily, starting 3 days after the implantation of tumor blocks, for
7 weeks. The group of mice which did not receive LH treatment
represented the “low LH group,” which mimicked the condition of
“pharmacologically inhibited LH secretion.”
Hence we developed four groups of mice:
Cell line injected Treatment with LH
Group 1 Hec1A control Hec1A +
Group 2 Hec1A low LH Hec1A −
Group 3 Hec1A-LH-R control Hec1A-LH-R +
Group 4 Hec1A-LH-R low LH Hec1A-LH-R −
In any case, 4 weeks after the tumor implant, all the mice
were euthanized and the peritoneal cavities were explored to
evaluate the tumor engraftment into the uterus as well as the
presence of macro metastases (Table 1). Representative exam-
ples of macro metastases detected are reported in panel 2A. The
percentage of grafting of tissue blocks into the uteri was 93%
(25/27). The uteri were surgically removed and weighted. Histo-
logical examination of the uteri showed myometrial infiltration in
all the mice groups (Figure 2B). Immunohistochemical analysis
using anti-human MHC antibodies further confirmed myometrial
FIGURE 1 | Characterization of cell line over-expressing LH-R in vitro
and in vivo: cell proliferation and invasion. (A) Cell proliferation of Hec1A
and Hec1A-LH-R cells. Cells (2.5×104 cells/100µl) were cultured in 96-well
plates. After 24 h incubation, cell proliferation was evaluated with the
colorimetric WST-1 assay (the absorbance value is reported on y axes).
Histograms represent the mean of the absorbance value±SEM (error
bars). Statistical analysis was performed with Student’s t test. (B,B′) Cell
invasion of Hec1A and Hec1A-LH-R cells. Cell invasion was evaluated using
a Boyden chamber system where a Matrigel-coated porous membrane
(8µm pore diameter) was inserted as described in Section “Materials and
Methods.” At time 0, recombinant LH was added or not to the medium. The
number of migrated cells was determined after 24 h of incubation. Cells
were fixed and stained with Diff–Quick staining solution, and counted on
the whole migration field at ×40 magnification. In (B) pictures relative to
representative membrane for Hec1A and Hec1A-LH-R cells, in the
presence or in the absence of LH, are reported. Histograms in (B′)
represent the mean of migrated cells±SEM (error bars). Statistical analysis
was performed with Student’s t test.
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Table 1 | Evaluation of distant metastasis in the orthotopic experimental model of endometrial cancer.
Lymph nodes Bladder Spleen Liver Diaphragm Lung
Hec1A control 5/5 (100) 3/5 (60) 1/5 (20) 0/5 (0) 1/5 (20) 1/4 (25)
Hec1A low LH 4/4 (100) 2/4 (50) 0/4 (0) 0/4 (0) 0/4 (0) 0/4 (0)
Hec1A-LH-R control 9/9 (100) 7/9 (78) 2/9 (22) 0/9 (0) 3/9 (33) 6/6 (100)
Hec1A-LH-R low LH 8/8 (100) 6/8 (75) 2/8 (25) 0/8 (0) 2/8 (25) 4/5 (80)
Screening for macrometastases in different organs of mice involved in the orthotopic experimental model of endometrial cancer. In the left column are reported the
group of mice and different cell lines injected and treatment used. The number of mice with macrometastases and the total number of mice analyzed are separated
by slashes. Percentages of mice with macrometastases are reported in parenthesis.
The statistical significance of differences between experimental group was calculated with Kruskal–Wallis test (non-parametric ANOVA).
infiltration (Figure 2C). No difference in the extent of myometrial
infiltration in the four groups was observed. The mean weight
of the uteri of mice injected with Hec1A-LH-R and treated with
LH (i.e., group 3) was lower than that of all the other experimen-
tal groups (Figure 2D). This fact can be traced back to a higher
capacity of spreading out of, more than proliferating inside, the
uterus conferred to EC cells by LH-R over-expression, and further
potentiated by the high levels of serum LH obtained by treating
the mice with rLH.
Mice developed macro metastases in the para-aortic nodes in
50% of the cases. The histological analysis showed lymph node
metastases in 100% of the cases (Table 1; Figure 2A). Lymph node
lesions displayed histological and cytological features of the orig-
inal tumor cells, including a solid growth pattern (Figures 2E,F).
Lymph node invasion was quantified and the invasion index calcu-
lated: the invasion index of lymph nodes of mice implanted with
Hec1A-LH-R in control (high LH) conditions was significantly
higher than that of mice implanted with Hec1A in control con-
ditions. No effect of LH withdrawal was observed (Figure 2G).
Moreover, LH-R over-expression conferred a higher capacity of
local invasion (i.e., bladder, spleen, and diaphragm) to EC cells
(Table 1; Figure 2A).
Finally, we evaluated the number of distant metastases in the
lungs of the four groups of mice (Figure 3). The mice injected with
Hec1A cells and treated daily with LH mimicking the condition
of menopause, i.e., high levels of circulating LH (group 1) showed
the capability, although at low levels, to develop distant metastases
[25% of cases with lung metastases (Table 1)]. On the other hand,
mice injected with Hec1A cells with undetectable levels of circu-
lating LH (group 2), did not develop distant metastases (Table 1).
The frequency of lung metastases increased significantly in mice
injected with Hec1A-LH-R, 80% in mice with low levels of LH
(group 4) and 100% in mice with high levels of circulating LH
(group 3).
The morphometric analysis of the areas of tumor invasion
allowed us to calculate the invasion index: the lungs of mice
belonging to groups 1 and 2 showed a very low invasion index.
Notably, mice injected with Hec 1A-LH-R (group 3) showed
the highest pulmonary metastatization (100% of cases with lung
metastases) and the highest lung invasion index (Figure 3A, see
also arrows in Figure 3B). In these mice, LH withdrawal (group 4,
i.e., Hec1a-LH-R low LH) produced a significant reduction in lung
metastasization [both percentage of lung metastases and invasion
index (see Figure 3C; Table 1)].
DISCUSSION
We evaluated the effect of LH-R on invasiveness of EC, using
Hec1A cells, a human EC cell line which expresses the LH-R
at low levels (11) as a model. In particular, we produced and
characterized Hec1A cells stably transfected with, and hence over-
expressing, the human LH-R (Hec1A-LH-R cells). In agreement
with what previously observed (11), the proliferation rate in vitro
of Hec1A-LH-R cells was not significantly different from that of
Hec1A cells, either in the absence or in the presence of exoge-
nous LH. On the other hand, cell invasiveness, triggered by LH
addition, was significantly higher in Hec1A-LH-R cells compared
to Hec1A cells. On the whole, these data confirm that a pos-
itive correlation exists between the level of LH-R expressed by
EC cells (11) and primary EC samples (12) and cell invasiveness
in vitro.
To better demonstrate this, and to have a model closer to
what happens in the human setting, we developed an appro-
priate mouse preclinical model. The model consists in athymic
nu/nu mice which received an implant of very small tumor block
(1 mm3 and weighting about 40 mg each) in the uterine wall.
The tumor blocks we implanted were obtained from subcuta-
neous masses obtained after injection of either Hec1A-LH-R or
Hec1A cells. Athymic nude mice are a very good model for our
goal, since they display severe deficiencies in reproductive func-
tion such as delayed ovulation and the females are usually sterile.
Moreover gonadotropins are totally absent in these mice. Hence
to make the model closer to the condition of menopause, i.e.,
high levels of circulating LH, the mice were treated daily with
high doses of rLH. On the whole, the preclinical model we devel-
oped, not only provides the proper microenvironment, i.e., the
uterus, which allows the growth of EC cells, as well as the emer-
gence of subpopulations of tumor cells with higher invasiveness
and metastatic potential, but also better mimicks those ECs which
develop during the post menopause, when high levels of LH
occurs.
The use of such model allowed us to conclude that (a) the
over-expression of the LH-R on the membrane of EC cells, is
critical to make EC cells to become more aggressive, and capa-
ble of invading the myometrium as well as surrounding organs,
in particular para-aortic lymph nodes; (b) the concomitant over-
expression of the LH-R and high, stable, levels of serum LH, make
EC cells capable of reaching the lung and give rise to lung metas-
tases; (c) the withdrawal of LH impedes EC cells to metastasize to
the lung.
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FIGURE 2 | Effects of LH-R over-expression and LH treatment in the
orthotopic xenograft model of endometrial cancer (EC).
(A,A′) Macroscopic view of representative examples of macrometastes
detected at the para-aortic lymph nodes and at diaphragm respectively.
(B) Histological characterization of the orthotopic EC model. Hematoxylin and
eosin (H&E) sections showing orthotopic grafts of Hec1A and Hec1A-LH-R
cell lines in direct contact and interaction with the uterus of the mice at the
area of implantation and the myometrial infiltration by tumor cells (20×).
(C) Immunohistochemistry staining of cancer cells in the myometrial wall.
Staining was performed with anti-MHC class I antibodies (H-300), 1: 100,
Santa Cruz (20× magnification). The insert in (C) is a magnification of the area
indicated by the square. Histograms in (D) represent the mean weight of the
uteri (±SEM) of mice implanted with Hec1A-LH-R cells or Hec1A and treated
or not with LH. Statistical analysis was performed with Student’s t test.
(E) Histological analysis showed para-aortic lymph node tumor cells invasion
(see arrows) (10× magnification). (F) Magnification (40×) of the tumor
invasion area (arrows). (G) Morphometric analysis of invasion of lymph nodes
in between all the different treatments was performed and histograms
reported represent the mean of the area of invasion/microscopic field (±SEM)
of lymph nodes in between all the different treatments.
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FIGURE 3 | Effects of LH-R over-expression and LH on distant
metastases in the orthotopic xenograft model of endometrial cancer.
(A,B) Hematoxylin and eosin (H&E) sections of lung metastases from mice
orthotopically engrafted Hec1A and from mice orthotopically engrafted
Hec1A-LH-R. Tumor cells (see arrows) are present in the lung parenchyma
and inside vessels (40× magnification). (C) Morphometric analysis of tumor
cells invasion in the lungs. Histograms represent the mean of the area of
invasion±SEM (error bars). Mann–Whitney test has been performed
(p=0.0043). Asterisk indicate statistical significance; p< 0.05.
CONCLUDING REMARKS
On the whole, the present paper identifies LH-R as a pro-
metastatic molecular device in EC, further stressing previous
suggestions (11, 12, 17). Moreover, data obtained in the ortho-
topic/menopausal mouse model strongly suggest the use of LH-R
detection as a diagnostic tool to identify high risk EC patients.
Finally, the possibility of treating LH-R positive, high risk EC cases,
with Gn-RH analogs could be proposed.
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